학술논문
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Document Type
article
Author
Yasunori Murata, MD, PhD; Shigeru Tanzawa, MD, PhD; Toshihiro Misumi, PhD; Hiroshige Yoshioka, MD, PhD; Eisaku Miyauchi, MD, PhD; Kiichiro Ninomiya, MD, PhD; Masafumi Takeshita, MD, PhD; Kensaku Ito, MD, PhD; Tatsuro Okamoto, MD, PhD; Shunichi Sugawara, MD, PhD; Yosuke Kawashima, MD; Kazuki Hashimoto, MD; Masahide Mori, MD, PhD; Akihiko Miyanaga, MD, PhD; Anna Hayashi, MD; Hisashi Tanaka, MD, PhD; Ryoichi Honda, MD, PhD; Masafumi Nojiri, MD, PhD; Yuki Sato, MD; Akito Hata, MD; Ken Masuda, MD, PhD; Toshiyuki Kozuki, MD, PhD; Takahisa Kawamura, MD, PhD; Takuji Suzuki, MD, PhD; Teppei Yamaguchi, MD, PhD; Kazuhiro Asada, MD, PhD; Satoshi Tetsumoto, MD, PhD; Hiroshi Tanaka, MD, PhD; Satoshi Watanabe, MD, PhD; Yukihiro Umeda, MD, PhD; Kakuhiro Yamaguchi, MD, PhD; Shoichi Kuyama, MD, PhD; Kosuke Tsuruno, MD, PhD; Yuki Misumi, MD, PhD; Hiroshi Kuraishi, MD, PhD; Ken Yoshihara, MD, PhD; Akira Nakao, MD, PhD; Akihito Kubo, MD, PhD; Toshihiko Yokoyama, MD, PhD; Kana Watanabe, MD, PhD; Nobuhiko Seki, MD, PhD
Source
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Subject
Language
English
ISSN
2666-3643
Abstract
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previously treated with immune checkpoint inhibitors (ICIs) remain unknown. Methods: This multicenter, retrospective, cohort study assessed the efficacy and tolerability of GCN initiated between November 1, 2019 and March 31, 2022 as second-line to fourth-line treatment in patients with advanced LSqCC who had been pretreated with ICIs. The primary end point was progression-free survival (PFS). Results: A total of 93 patients from 35 institutions in Japan were enrolled. The median PFS, median overall survival (OS), and objective response rate were 4.4 months (95% confidence interval [CI]: 3.8–5.3), 13.3 months (95% CI: 9.6–16.5), and 27.3% (95% CI: 18.3–37.8), respectively. The median PFS, median OS, and objective response rate for second-line, third-line, and fourth-line treatment groups were 4.8 months, 3.8 months, and 4.3 months (p = 0.24); 15.7 months, 11.6 months, and 10.1 months (p = 0.06); and 31.0%, 13.6%, and 37.5% (p = 0.22), respectively. The severity of GCN-related skin disorders was associated with longer PFS (p < 0.05) and OS (p < 0.05). The frequencies of grade ≥3 skin disorders, hypomagnesemia, pneumonitis, and febrile neutropenia were 16.1%, 7.5%, 1.1%, and 4.3%, respectively. There were no treatment-related deaths. Conclusions: GCN for ICI-pretreated patients with LSqCC seems tolerable and offers promising efficacy regardless of treatment line, and ICI pretreatment might enhance GCN efficacy.